DE2350207A1 - 2-amino-derivate des 4,8-dimethoxyfuranobenzoxazols, verfahren zu ihrer herstellung und diese derivate enthaltende arzneimittel - Google Patents
2-amino-derivate des 4,8-dimethoxyfuranobenzoxazols, verfahren zu ihrer herstellung und diese derivate enthaltende arzneimittelInfo
- Publication number
- DE2350207A1 DE2350207A1 DE19732350207 DE2350207A DE2350207A1 DE 2350207 A1 DE2350207 A1 DE 2350207A1 DE 19732350207 DE19732350207 DE 19732350207 DE 2350207 A DE2350207 A DE 2350207A DE 2350207 A1 DE2350207 A1 DE 2350207A1
- Authority
- DE
- Germany
- Prior art keywords
- derivatives
- formula
- dimethoxy
- amino
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 4
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical class NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 title description 2
- 238000004519 manufacturing process Methods 0.000 title description 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 29
- -1 propylamino, phenyl amino, dimethyl amino Chemical group 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 208000025865 Ulcer Diseases 0.000 description 5
- 238000000921 elemental analysis Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 2
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 241001279009 Strychnos toxifera Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229960005152 pentetrazol Drugs 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 229960005453 strychnine Drugs 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 241000384942 Premna serratifolia Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010053692 Wound complication Diseases 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- LYHIYZUYZIHTCV-UHFFFAOYSA-N cyclopenta[b]pyran Chemical compound C1=COC2=CC=CC2=C1 LYHIYZUYZIHTCV-UHFFFAOYSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- ZZYJNUAUZDNLRL-UHFFFAOYSA-N furo[2,3-g][1,3]benzoxazole Chemical compound O1C=CC2=C1C=CC1=C2OC=N1 ZZYJNUAUZDNLRL-UHFFFAOYSA-N 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000009090 positive inotropic effect Effects 0.000 description 1
- 229940072033 potash Drugs 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/86—Benzo [b] furans; Hydrogenated benzo [b] furans with an oxygen atom directly attached in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR7235861A FR2201886B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1972-10-10 | 1972-10-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
DE2350207A1 true DE2350207A1 (de) | 1974-04-25 |
Family
ID=9105428
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE19732350207 Pending DE2350207A1 (de) | 1972-10-10 | 1973-10-05 | 2-amino-derivate des 4,8-dimethoxyfuranobenzoxazols, verfahren zu ihrer herstellung und diese derivate enthaltende arzneimittel |
Country Status (14)
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0401334D0 (en) * | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
-
1972
- 1972-10-10 FR FR7235861A patent/FR2201886B1/fr not_active Expired
-
1973
- 1973-10-02 BE BE136261A patent/BE805569A/xx unknown
- 1973-10-05 DE DE19732350207 patent/DE2350207A1/de active Pending
- 1973-10-05 GB GB4661473A patent/GB1374400A/en not_active Expired
- 1973-10-08 ZA ZA737829*A patent/ZA737829B/xx unknown
- 1973-10-09 JP JP48112908A patent/JPS4993396A/ja active Pending
- 1973-10-09 AU AU61152/73A patent/AU474987B2/en not_active Expired
- 1973-10-09 SU SU1962870A patent/SU512705A3/ru active
- 1973-10-09 ES ES419485A patent/ES419485A1/es not_active Expired
- 1973-10-09 SE SE7313721A patent/SE384682B/xx unknown
- 1973-10-09 LU LU68584A patent/LU68584A1/xx unknown
- 1973-10-10 NL NL7313967A patent/NL7313967A/xx unknown
- 1973-10-10 CA CA183,027A patent/CA996108A/fr not_active Expired
- 1973-10-10 CH CH1444373A patent/CH575946A5/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU6115273A (en) | 1975-04-10 |
SU512705A3 (ru) | 1976-04-30 |
JPS4993396A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1974-09-05 |
FR2201886B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1976-05-21 |
SE384682B (sv) | 1976-05-17 |
NL7313967A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1974-04-16 |
FR2201886A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1974-05-03 |
ZA737829B (en) | 1974-08-28 |
LU68584A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1973-12-14 |
ES419485A1 (es) | 1976-04-01 |
GB1374400A (en) | 1974-11-20 |
CH575946A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1976-05-31 |
CA996108A (fr) | 1976-08-31 |
BE805569A (fr) | 1974-04-02 |
AU474987B2 (en) | 1976-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE1795836C2 (de) | 3-MethyI-2,3,4,4a-tetrahydro-lH- pyrazine [1,2-f] phenanthridin | |
DE2634288C3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
CH630364A5 (de) | Verfahren zur herstellung von neuen aminoalkylheterocyclen und ihren saeureadditionssalzen. | |
DE1958918A1 (de) | Chemische Verfahren und Produkte | |
DE2163911B2 (de) | 2-Aminomethyl-phenole, Verfahren zur Herstellung derselben und diese enthaltende Arzneimittel | |
DE2128375C3 (de) | Basische substituierte Alkylidenamino-oxyalkyl-carbonsäureester, deren Säureadditionssalze, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate | |
DE3035688C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
DE2621082C2 (de) | Piperazinderivat, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel | |
DE2350207A1 (de) | 2-amino-derivate des 4,8-dimethoxyfuranobenzoxazols, verfahren zu ihrer herstellung und diese derivate enthaltende arzneimittel | |
DE2815088A1 (de) | 5-piperazinylsubstituierte derivate von pyrido- eckige klammer auf 2.3-b eckige klammer zu -benzothiazepin(1.5), ihre herstellung und pharmazeutische mittel | |
DE2531829C2 (de) | N-(3,4,5-Trimethoxycinnamoyl)-N'- (2'-pyrrolidinon-1'-carbonylmethyl) -piperazin, Verfahren zu dessen Herstellung und diese Verbindung enthaltende Arzneimittel | |
DE3204373A1 (de) | Thiazaspiranderivate, verfahren zu ihrer herstellung und arzneimittel | |
DE2327414C2 (de) | Verfahren zur Herstellung von N-(Diethylaminoethyl)-2-methoxy-5-methylsulfonylbenzamid und seinen Additionssalzen | |
DE2333831A1 (de) | 1-(2'-benzoyl-aeth-1'-yl)-2-(4"cinnamyl-piperazin-1"-yl-methyl)benzimidazole, verfahren zu ihrer herstellung und ihre therapeutische verwendung | |
DE1817861C3 (de) | N-alkylierte 3,4-Methylendioxymandelsäureamidine und deren pharmakologisch nicht giftige Säureanlagerungssalze und diese enthaltende pharmazeutische Mittel. Ausscheidung aus: 1811804 | |
DE2238115C3 (de) | 5-Cinnamoyl-benzofuranderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel | |
EP0284892B1 (de) | Neue 2-Thienyloxyessigsäurederivate, ein Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate | |
DE2341894A1 (de) | Substituierte 2-phenyl-2,3-dihydrobenzo eckige klammer auf b eckige klammer zu thiophen-1,1-dioxyd-derivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel | |
DE3026964A1 (de) | 2-amino-3-(alkylthiobenzoyl)- phenylessigsaeuren, deren ester und metallsalze, pharmazeutische zubereitungen, welche diese verbindungen enthalten und deren verwendung | |
DE2408603A1 (de) | Substituierte (5,6,e)oxazinindole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel | |
DE2221281A1 (de) | Pyrazolderivate und Verfahren zu ihrer Herstellung | |
DE2357320C3 (de) | 3-Metnyl-8-methoxy-(3H)-l,2,5.6tetrahydropyrazino- [1,23-ab] - ß -carbolin, seine Salze sowie ein Verfahren zu deren Herstellung und Arzneimittel | |
DE2328384A1 (de) | 5-aminomethyl- eckige klammer auf (5',6'e)oxazinoindole eckige klammer zu, verfahren zu ihrer herstellung und ihre therapeutische verwendung | |
DE2202046A1 (de) | Neue Piperazinacrylamidderivate,Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittelwirkstoff | |
DE2304224C3 (de) | 4'-Aminomethyl-dibenzo(b,e)-l 1oxepin-2'-spiro-l', 3'-dioxolan-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
OHJ | Non-payment of the annual fee |